Dexcom works with FDA after stolen scrapped G7 sensors enter market

Dexcom

Dexcom

DXCM

0.00

  • Dexcom identified theft of two scrapped Dexcom G7 sensor lots during a third-party destruction process, triggering engagement with the FDA and other authorities.
  • Affected lots 1725204004 and 1725069002 were sold into the market by third parties; users are advised not to use them.
  • Lot 1725204004 carries an increased risk of skin infection due to improper sterilization; lot 1725069002 has higher risk of no readings.
  • Dexcom traced sales to Pharmsource, a non-authorized distributor; pharmacies sourcing via it are urged to review inventory.
  • No severe adverse events have been reported; replacements are being offered to impacted users.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexCom Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605260930BIZWIRE_USPR_____20260526_BW622391) on May 26, 2026, and is solely responsible for the information contained therein.